Ohmeda NO2 trials for neonatal PPH should not use improved oxygenation as primary endpoint -- FDA cmte.
Executive Summary
OHMEDA NITRIC OXIDE TRIALS FOR NEONATAL PPH SHOULD NOT USE IMPROVED OXYGENATION as the primary endpoint, FDA's Cardiovascular & Renal Drugs Advisory Committee determined at its Aug. 28 meeting. The meeting was devoted to a discussion of guidelines for the development of inhaled nitric oxide for the treatment of persistent pulmonary hypertension of newborns, although the crux of the discussion was Ohmeda's choice of a primary endpoint for its clinical trial of inhaled nitric oxide for the condition. The committee voted unanimously that Ohmeda's proposed time-weighted oxygenation index is not an acceptable primary endpoint.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth